Perspective Therapeutics
CATX3.0000.33% ( -0.010 )
Perspective Therapeutics (CATX)
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer...
- Open
- 3.010
- High
- 3.120
- Low
- 2.980
- Prev. Close
- 3.010
- Volume
- 2.29M
- Turnover
- 6.92M
- Avg Price
- 3.020
- Bid/Ask Ratio
- --
- Amplitude
- 4.65%
- 52wk High
- 6.160
- Volume Ratio
- 2.81
- Turnover Ratio
- 3.08%
Perspective Therapeutics Analyst Rating
View MoreForecast & Rating
Aug 3, 2026Price forecast
$12.79326.19%
Forecast & RatingStrong buy
15analysts
- Strong buy80.00%
- Buy13.33%
- Hold6.67%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · Aug 1 at 02:40 AM
Perspective Therapeutics, Inc. $CATX Shares Bought by Avidity Partners Management LP
- PUBT · Jul 31 at 05:30 AM
Perspective Therapeutics to report Q2 2026 results after market close
- Market Beat · Jul 29 at 05:48 AM
1,055,409 Shares in Perspective Therapeutics, Inc. $CATX Bought by Yu Fan
- PUBT · Jul 28 at 05:35 AM
Perspective Therapeutics wins EU orphan drug status for (212Pb) VMT-α-NET in GEP-NETs
- Market Beat · Jul 27 at 04:53 AM
791,555 Shares in Perspective Therapeutics, Inc. $CATX Bought by Octagon Capital Advisors LP
- MSN · Jul 17 at 12:21 PM
As Q2 earnings kick off, these small-cap stocks earn an A+ for profitability
